Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
…, RA Fowler, JS Lazar, G Shi, P Wung… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial
…, R Blanco, Y Duan, Y Li, AL Pangan, P Wung… - The Lancet, 2022 - thelancet.com
Background Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients
with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in …
with ankylosing spondylitis. We aimed to assess the efficacy and safety of upadacitinib in …
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Y Allanore, P Wung, C Soubrane, C Esperet… - Annals of the …, 2020 - ard.bmj.com
Objectives Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented
immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered…
immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered…
[HTML][HTML] Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 …
…, X Zeng, Y Sui, X Bu, AL Pangan, P Wung… - Annals of the …, 2022 - ard.bmj.com
Objectives To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in
patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological …
patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological …
SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)
…, L Richeldi, B Crestani, P Wung… - European …, 2018 - Eur Respiratory Soc
A phase 2b trial ( NCT02345070 ) was conducted to evaluate the efficacy and safety of two
dose levels/regimens of SAR156597 (a bispecific IgG4 antibody that binds and neutralises …
dose levels/regimens of SAR156597 (a bispecific IgG4 antibody that binds and neutralises …
Herpes zoster in immunocompromised patients: incidence, timing, and risk factors
PK Wung, JT Holbrook, GS Hoffman, AK Tibbs… - The American journal of …, 2005 - Elsevier
PURPOSE: To evaluate the risk factors for herpes zoster as well as the incidence and timing
of this complication in patients who were treated with immunosuppression because of active …
of this complication in patients who were treated with immunosuppression because of active …
Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis
PK Wung, T Anderson, KR Fontaine… - Arthritis Care & …, 2008 - Wiley Online Library
Objective Weight gain is a side effect of glucocorticoid (GC) use, but the natural history and
health implications of changes in weight that occur during the treatment of inflammatory …
health implications of changes in weight that occur during the treatment of inflammatory …
Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon
A Fava, PK Wung, FM Wigley… - Arthritis care & …, 2012 - Wiley Online Library
Objective The RhoA/Rho kinase pathway plays a pivotal role in cold‐induced vasoconstriction,
vascular smooth muscle cells function, and vascular homeostasis. This study evaluates …
vascular smooth muscle cells function, and vascular homeostasis. This study evaluates …
Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
…, H Kameda, Y Li, X Bu, A Shmagel, P Wung… - Arthritis Research & …, 2023 - Springer
Background Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an
acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS …
acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS …
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing
spondylitis (AS) has not been previously reported. Methods In SELECT-AXIS 1, patients …
spondylitis (AS) has not been previously reported. Methods In SELECT-AXIS 1, patients …
